EluviaTM Drug-Eluting Stent (DES) was designed to address the peak of restenosis1, providing continuous release of paclitaxel for up to 12 months, unlike other drug-eluting stents which only release it for 2-3 months, ensuring ongoing protection during the critical period.
Eluvia™ Drug Eluting Stent (DES) is the only commercially available DES to have been tested – and proven superior – in three separate head-to-head randomised controlled trials.
Proven superiority
In the unmatched performance levels of the Eluvia™ Drug Eluting Stent (DES), we have invested prospective randomised controlled head-to-head trials against competitive technologies.
The EMINENT2, IMPERIAL3, and SPORTS4 Trials each met their primary endpoint and provide you with level-1 evidence of Eluvia’s superior primary patency versus BMS and Zilver PTX, respectively.
EMINENT and IMPERIAL RCT
We invested in 2 randomised controlled trials that demonstrated Eluvia's superiority over both BMS and Zilver PTX.
More Confidence with Level-1 RCTs
SUPERIOR to both BMS and Zilver PTX in RCTs
SPORTS RCT
Eluvia’s 1-year drug elution delivers statistically superior outcomes to BMS and DCB.
Consistency performance
The evidence of Eluvia’s superior primary patency is not limited to the controlled setting of RCTs – in study after study, real-world evidence confirms consistently high (90%) primary patency rates in patients that reflect the real-world challenges you face in treating PAD in the SFA– long lesions, complex lesions and patients with compromising comorbidities2-12
More Evidence in real world patients
Consistent performance for all your patients.
Lowest TLR rate of any SFA stent at 2 years
Studies supporting Eluvia’s superiority extend beyond primary patency and one-year follow-up to show durable outcomes. When you choose Eluvia to treat PAD in the SFA – even in patients with complex lesions or comorbidities – it’s an evidence-based decision, with studies showing that 9 out of 10 patients are TLR-free after two years.2-12
More Successful Outcomes for your patients
Lowest TLR rate of any SFA stent at 2 years.
References
Iida O, Uematsu M, Soga Y, et al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenosis. Catheter Cardiovasc Interv. 2011;78(4):611–617.
Imperial: Gray WA, Keirse K, Soga Y, et al; IMPERIAL investigators. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;27;392(10157):1541–1551. Müller-Hülsbeck S, Benko A, Soga Y, et al. Two-year efficacy and safety results from the IMPERIAL Randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–375.
EMINENT: Gouëffic Y, et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: Primary results of the EMINENT randomized trial. Circulation. 2022;146:1564–1576.
SPORTS: Tepe G. SPORTS. TCT 2023, October 24, 2023, San Francisco, CA.
Majestic: Müller-Hülsbeck S, Charing Cross 2015. Müller-HülsbeckS, et al. Cardiovasc Intervent Radiol. 2017;40(12):1832-1838.
Regal: Lansik W. Real world all comers data from the REGAL registry – 2-year results. Presented at LINC 2023.
Auckland: Holden, A. Single Centre Long-Term Experience with the Boston Scientific Eluvia DES in Femoro-popliteal Artery Occlusive Disease. LINC 2020.
IMPERIAL Long: Müller-Hülsbeck S, et al. Two-year efficacy and safety results from the IMPERIAL Randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–375.
Capsicum: Iida O, Takahara M, Soga Y, et al; CAPSICUM Investigators. 1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration. JACC Cardiovasc Interv. 2022 Mar 28;15(6):630–638. Iida LINC 2023.
Desafinado: Kum S, Ipema J, Huizing E, et al. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia. Vasc Med. 2021;26(3):267–272.
Muenster: Stavroulakis K, Torsello G, Bosiers M. 2-Year Outcomes of the Eluvia Drug-Eluting Stent for the Treatment of Complex Femoropopliteal Lesions. JACC Cardiovasc Interv. 2021;14(6):692–701.
Ultimate: Ichihashi S, Takahara M, Yamaoka T, et al. Drug eluting versus covered stent for femoropopliteal artery lesions: Results of the ultimate study. Eur J Vasc Endovasc Surg. 2022;64(4);359–366.
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.